Amyotrophic Lateral Sclerosis Market Expected to Experience Major Growth by 2034, According to DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma

The Key Amyotrophic Lateral Sclerosis Companies in the market include - Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, and others.
To strategically aid Amyotrophic Lateral Sclerosis companies developing drugs for Amyotrophic Lateral Sclerosis, DelveInsight launched a report titled as "Amyotrophic Lateral Sclerosis Market Insight, Epidemiology And Market Forecast - 2034". This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Amyotrophic Lateral Sclerosis market.

To Know in detail about the Amyotrophic Lateral Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Amyotrophic Lateral Sclerosis Market Forecast [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Key Highlights from Amyotrophic Lateral Sclerosis market Report:

*
The Amyotrophic Lateral Sclerosis market size in the 7mm was valued ~USD 1 billion in 2023 and is expected to grow with a significant CAGR during the forecast period (2020-2034)

*
In January 2025, The U.S. Food and Drug Administration (FDA) authorized Zydus Lifesciences to conduct a randomized Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for the treatment of amyotrophic lateral sclerosis (ALS). This multi-center, placebo-controlled, double-blind study will evaluate the therapy's safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients.

*
In November 2024, California-based trial access company, WideTrial, is set to take part in a National Institutes of Health-funded initiative to expand pre-approval access to the investigational Amyotrophic Lateral Sclerosis (ALS) drug, ibudilast, supported by $22 million in funding. This initiative aims to enhance access to the experimental treatment, which is being evaluated for its potential to slow ALS progression, particularly for patients who do not qualify for current clinical trials. The funding is provided through a grant from the National Institute of Neurological Disorders and Stroke (NINDS).

*
In November 2024, New Jersey-based biopharmaceutical company PTC Therapeutics announced that its Phase II trial of utreloxastat for amyotrophic lateral sclerosis (ALS) did not achieve its primary endpoints, leading to the trial's termination. The global, placebo-controlled Phase II study (NCT05349721) failed to demonstrate a reduction in plasma neurofilament light chains (NfL), a key biomarker used to assess disease progression and treatment impact.

*
In November 2024, France-based MaaT Pharma is preparing for a Phase II study of its immune system modulator following the successful completion of its Phase Ib trial in amyotrophic lateral sclerosis (ALS) patients. The exploratory single-arm, open-label study, IASO (NCT05889572), achieved all primary endpoints, demonstrating that MaaT-033 was both safe and well tolerated. The company expects to share findings from the trial's secondary endpoints soon.

*
In September 2024, Zydus, a global pharmaceutical company focused on drug discovery, has successfully completed its Phase II(a) clinical trial of the NLRP3 inhibitor 'Usnoflast (ZYIL1)' in patients with amyotrophic lateral sclerosis (ALS). ALS is characterized by neuroinflammation and rapid neurodegeneration, with axonal damage leading to the accumulation of neurofilaments in the cerebrospinal fluid (CSF) before they gradually enter the bloodstream.

*
The market size for ALS in the US was estimated at approximately USD 920 million in 2023, with expectations for growth throughout the forecast period (2024-2034).

*
RADICAVA is expected to be the top performer in the current ALS market, with projected revenue reaching USD 923 million in the US by 2034.

*
By 2034, Masitinib in combination with riluzole is projected to generate the highest revenue among emerging therapies, reaching USD 37 million in Japan.

*
Currently, ALS treatments include EXSERVAN (Riluzole oral film), RELYVRIO, QALSODY, RADICAVA (edaravone injection), RADICAVA ORS (edaravone oral suspension), NEUDEXTA, TIGLUTEK, and RILUTEK, along with other symptomatic therapies such as anti-epileptic drugs, opioids, NSAIDs, diuretics, SSRIs, and antidepressants.

*
In 2023, the US reported the highest number of ALS cases among the 7MM, with approximately 26,000 cases, and this number is expected to rise throughout the forecast period.

*
In 2023, Germany had the highest number of diagnosed prevalent ALS cases among the EU4 and the UK, whereas Spain had the fewest cases.

*
In 2023, the majority of ALS cases originated from the spinal site, with approximately 15,000 cases, followed by the bulbar site of onset. Other uncertain regions also contributed to the onset of ALS cases.

*
Estimates indicate that in Japan, ALS was most common in the 70-79 age group, followed by the 60-69 and 50-59 age groups.

*
Key Amyotrophic Lateral Sclerosis Companies: Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, and others

*
Key Amyotrophic Lateral Sclerosis Therapies: Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, AP-101, MN-166 (ibudilast), and others

Amyotrophic Lateral Sclerosis Country based Treatment Overview:

The Amyotrophic Lateral Sclerosis market research report provides current treatment practices, emerging drugs, Amyotrophic Lateral Sclerosis market share of the individual therapies, current and forecasted Amyotrophic Lateral Sclerosis market Size from 2020 to 2034 segmented by seven major markets.

Lou Gehrig's disease, often known as amyotrophic lateral sclerosis (ALS), is a collection of uncommon neurological disorders primarily affecting the nerve cells (neurons) in charge of voluntary muscular movement. Movements like chewing, walking, and talking are produced by voluntary muscles. Since the illness is progressive, the symptoms worsen with time.

Get a Free sample for the Amyotrophic Lateral Sclerosis Market Report:

https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market [https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Amyotrophic Lateral Sclerosis Epidemiology Insights:

The Amyotrophic Lateral Sclerosis epidemiology section offers insights into the past and present patient population affected by the disease, along with predicted trends across seven major countries. It assists in understanding the reasons behind current and anticipated trends by analyzing multiple studies and opinions from key experts.

*
In 2023, the US had the highest prevalence of ALS among the 7MM, with approximately 26,000 cases. This number is anticipated to rise throughout the forecast period.

*
In 2023, Germany had the highest number of diagnosed ALS cases among the EU4 and the UK, whereas Spain had the fewest cases.

*
The primary onset sites for ALS include the bulbar and spinal regions, along with other indeterminate areas. In 2023, spinal onset ALS had the highest number of cases, totaling 15,000, followed by bulbar onset.

*
The Amyotrophic Lateral Sclerosis epidemiology based on gender analyzed that males are more affected than females in case of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis Epidemiology Segmentation:

*
Total Prevalence of Amyotrophic Lateral Sclerosis

*
Prevalent Cases of Amyotrophic Lateral Sclerosis by severity

*
Gender-specific Prevalence of Amyotrophic Lateral Sclerosis

*
Diagnosed Cases of Episodic and Chronic Amyotrophic Lateral Sclerosis

Download the report to understand which factors are driving Amyotrophic Lateral Sclerosis epidemiology trends @ Amyotrophic Lateral Sclerosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Amyotrophic Lateral Sclerosis Drugs and Key Companies

*
Engensis (VM202): Helixmith

*
SAR443820/DNL788: Sanofi/Denali Therapeutics

*
TPN-101: Transposon Therapeutics

*
Latozinemab (AL001/GSK4527223): Alector/GSK

*
PrimeC: NeuroSense Therapeutics

*
Tofersen (BIIB067): Biogen/Ionis

*
ION363: Ionis Pharmaceuticals

*
NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics

*
Reldesemtiv: Cytokinetics/Astellas Pharma

*
Pegcetacoplan (APL-2): Apellis Pharmaceuticals

*
Gold Nanocrystals/CNM-Au8: Clene Nanomedicine Biosciences

*
AP-101: AL-S Pharma

*
MN-166 (ibudilast): MediciNova

Discover more about therapies set to grab major Amyotrophic Lateral Sclerosis market share @ Amyotrophic Lateral Sclerosis Treatment Market [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Amyotrophic Lateral Sclerosis Market Forecast:

*
Potential Amyotrophic Lateral Sclerosis treatments are being developed in the mid- and late stages and could soon be released. The main participants in the market are Verdiperstat (Biohaven Pharmaceuticals), Masitinib (AB Science), Gold Nanocrystals/CNM-Au8 (Brainstorm-Cell Therapeutics), Tofersen/BIIB067 (Biogen/Ionis Pharmaceuticals), and others. This could lead to a rise in the market size in the upcoming years, helped along by a rise in the number of people with Amyotrophic Lateral Sclerosis diagnosis.

*
RADICAVA (edaravone) has been an effective therapy for ALS. Recently, oral RADICAVA got approved in the US for the treatment of patients with ALS to increase the patient compliance.

*
Most of the 7MM possess their own ALS registries, thereby providing a near precise country-wise number for diagnosed prevalent cases of the disease

Scope of the Amyotrophic Lateral Sclerosis Market Report:

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Amyotrophic Lateral Sclerosis Companies: Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others, and others

*
Key Amyotrophic Lateral Sclerosis Therapies: Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, AP-101, MN-166 (ibudilast), and others

*
Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies

*
Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Amyotrophic Lateral Sclerosis Unmet Needs, KOL's views, Analyst's views, Amyotrophic Lateral Sclerosis Market Access and Reimbursement

To know more about Amyotrophic Lateral Sclerosis companies working in the treatment market, visit @ Amyotrophic Lateral Sclerosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Amyotrophic Lateral Sclerosis market landscape.

*
Gain Competitive Edge in Indication Market : Understand the current landscape of the Amyotrophic Lateral Sclerosis market, including the competitive environment, key companies developing drugs for Amyotrophic Lateral Sclerosis, and their strategies. By analyzing market dynamics, treatment approaches, and emerging Amyotrophic Lateral Sclerosis therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

*
Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the Amyotrophic Lateral Sclerosis market. This involves recognizing areas where current Amyotrophic Lateral Sclerosis treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Amyotrophic Lateral Sclerosis. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

*
Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

*
Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Amyotrophic Lateral Sclerosis market with clarity and purpose.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=amyotrophic-lateral-sclerosis-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-helixmith-sanofi-denali-therapeutics-transposon-therapeutics-gsk-biogen-ionis-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.